OBJECTIVE： To evaluate evidence foundation of phamracogenetics personalized medication， and to provide reference for clinical application. METHODS： Using “phamracogenetics” “pharmacogenomics” and “gene polymorphism” as key words， related literatures and clinical guideline were retrieved from PubMed， CNKI， Wanfang database， and analyzed in respects of involved gene， site and drug types， etc. Evidences of package inserts of phamracogenetics biomarker were evaluated by using phamracogenetics practice and prevention evaluation guideline. RESULTS： 8 276 papers， 25 guidelines and 166 drug package inserts are available for analysis. The phamracogenetics literatures mostly focus on the relationship between some one gene and different drugs. In guidelines， some one specific gene can guide clinical application of multiple drugs in different fields. In drug package inserts， general level of clinical evidence is not high； detectable biomarkers is inadequate in category， and detection rate is only 38.06％ besides targeting preparation. CONCLUSIONS： Under the condition of low clinical evidence level the detection of pharmacogenetics biomarker should be conducted carefully， and basic study should be further strengthened.